Affiliation:
1. Institute of Cardiovascular Sciences University of Birmingham Birmingham UK
2. Department of Haematology University Hospitals Birmingham NHS Foundation Trust Birmingham UK
Abstract
AbstractPure red cell aplasia (PRCA) is characterised by normocytic normochromic anaemia, reticulocytopenia and reduced erythroid precursors in bone marrow. PRCA as an immune‐related adverse event secondary to immune checkpoint inhibitor (ICI) therapy is rare. Steroids are usually used first line to treat ICI‐induced PRCA. Here, we report a case of ICI‐induced PRCA with no response to steroids but where intravenous (IV) immunoglobulin was successfully used second line. ICI therapy was reinitiated following PRCA resolution. PRCA recurrence did not occur.
Funder
Birmingham Biomedical Research Centre